professional factory for 2492-87-7 - Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE – XD BIOCHEM
professional factory for 2492-87-7 - Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE – XD BIOCHEM Detail:
Catalog Number | XD90590 |
Product Name | Citicoline sodium |
CAS |
33818-15-4 |
Molecular Formula |
C14H25N4NaO11P2 |
Molecular Weight |
510.31 |
Storage Details | -20°C |
Harmonized Tariff Code | 29349990 |
Product Specification
Appearance | White Solid |
Assay |
99% |
Melting point |
250°C(dec.)(lit.) |
Boiling point |
°Cat760mmHg |
PSA |
238.17000 |
logP |
-0.14090 |
Solubility |
H2O: 100mg/mL |
Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non-US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group and the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had a favorable outcome on the Barthel Index at 90 days. There were no drug-related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.
Product detail pictures:
Related Product Guide:
With our loaded practical experience and thoughtful solutions, we now have been identified for a trusted provider for numerous intercontinental consumers for professional factory for 2492-87-7 - Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE – XD BIOCHEM , The product will supply to all over the world, such as: Nepal, Germany, Saudi Arabia, we are now looking forward to even greater cooperation with overseas customers based on mutual benefits. We will work wholeheartedly to improve our products and services. We also promise to work jointly with business partners to elevate our cooperation to a higher level and share success together. Warmly welcome you to visit our factory sincerely.
By Poppy from Croatia - 2018.10.31 10:02
This supplier's raw material quality is stable and reliable, has always been in accordance with the requirements of our company to provide the goods that quality meet our requirements.
By Norma from Mexico - 2017.06.19 13:51